Back to top

Analyst Blog

Recently, Cognizant Technology (CTSH - Analyst Report) extended its relationship with ING U.S., whereby the former can offer a broad array of insurance business process services to the latter. The agreement valued at $330 million spans seven years. 

The U.S. arm of Dutch-based ING Groep N.V. (ING - Snapshot Report), ING U.S. family of companies, offers a widespread array of financial services to retail and institutional clients in the U.S. These services include life insurance, retirement plans, mutual funds, managed accounts, alternative investments, institutional investment management, annuities, employee benefits and financial planning. 

As per the expanded agreement, Cognizant will now employ more than 1,000 ING U.S. employees in Minot, North Dakota and Des Moines, Iowa with the intent of creating a U.S.-based center of excellence for insurance and finance business process services. The expanded agreement is expected to build on Cognizant's ongoing success in providing specific technology systems management for ING U.S.

Being an integral part of the Cognizant's global delivery network, the center will empower the company to provide a broad range of business process services spanning the insurance and financial services industries. The company already provides business process services to more than 40 clients in these industries.

Under the multiyear agreement, Cognizant will buy ING U.S.'s existing facility in Minot, North Dakota. The company will also sub-lease offices in the current ING U.S. facility in Des Moines, Iowa, thereby providing business and workplace continuity for ING U.S. customers and the employees transitioning to Cognizant.

Meanwhile, earnings estimates for 2012 have dropped marginally in the last few days as management trimmed its outlook for 2012. Cognizant did not experience a strong acceleration in growth as it normally does at the end of the first quarter.

Also, contradictory to management’s expectations, North America was weaker. In particular, the banking portion of the financial services segment and the pharmaceuticals portion of the healthcare segment were the laggards.

We continue to maintain a Neutral recommendation on Cognizant in the long run. However, the near-term weakness forces us to have a Zacks #4 Rank, which translates into a short-term rating of Sell.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SYNAPTICS I… SYNA 78.11 +8.14%
CENTURY ALU… CENX 19.88 +5.74%
GREEN PLAIN… GPRE 39.41 +5.12%
PILGRIM'S P… PPC 28.82 +3.08%
THE PANTRY… PTRY 18.41 +2.79%